Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
338.7 USD | -0.18% | -2.78% | +13.11% |
May. 16 | Cigna Insider Sold Shares Worth $2,073,449, According to a Recent SEC Filing | MT |
May. 16 | Cigna Insider Sold Shares Worth $3,728,629, According to a Recent SEC Filing | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
- The company's Refinitiv ESG score, based on a ranking of the company relative to its industry, comes out particularly well.
Strengths
- The company is one of the most undervalued, with an "enterprise value to sales" ratio at 0.51 for the 2024 fiscal year.
- Given the positive cash flows generated by its business, the company's valuation level is an asset.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- Analyst opinion has improved significantly over the past four months.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
- There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company does not generate enough profits, which is an alarming weak point.
- The company is not the most generous with respect to shareholders' compensation.
- For the last few months, analysts have been revising downwards their earnings forecast.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Managed Healthcare
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+13.11% | 96.22B | B- | ||
-0.35% | 483B | B- | ||
+16.15% | 127B | A- | ||
-22.19% | 42.92B | A- | ||
+5.19% | 41.66B | B- | ||
-3.79% | 20.37B | B- | ||
-15.68% | 1.39B | B- | ||
-6.52% | 441M | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- CI Stock
- Ratings Cigna